Engineering microrobots for targeted cancer therapies from a medical perspective.

Journal: Nature communications
PMID:

Abstract

Systemic chemotherapy remains the backbone of many cancer treatments. Due to its untargeted nature and the severe side effects it can cause, numerous nanomedicine approaches have been developed to overcome these issues. However, targeted delivery of therapeutics remains challenging. Engineering microrobots is increasingly receiving attention in this regard. Their functionalities, particularly their motility, allow microrobots to penetrate tissues and reach cancers more efficiently. Here, we highlight how different microrobots, ranging from tailor-made motile bacteria and tiny bubble-propelled microengines to hybrid spermbots, can be engineered to integrate sophisticated features optimised for precision-targeting of a wide range of cancers. Towards this, we highlight the importance of integrating clinicians, the public and cancer patients early on in the development of these novel technologies.

Authors

  • Christine K Schmidt
    Manchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, 555 Wilmslow Road, Manchester, M20 4GJ, UK. christine.schmidt@manchester.ac.uk.
  • Mariana Medina-Sánchez
    Micro and Nano-biomedical Engineering Group at the Leibniz IFW in Dresden, Germany.
  • Richard J Edmondson
    Gynaecological Oncology, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
  • Oliver G Schmidt
    Institute for Integrative Nanosciences at the Leibniz IFW in Dresden, Germany. Oliver G. Schmidt is also Professor of Material Systems for Nanoelectronics at Technische Universität Chemnitz, Germany.